PMID- 26445329
OWN - NLM
STAT- MEDLINE
DCOM- 20160325
LR  - 20181113
IS  - 1414-431X (Electronic)
IS  - 0100-879X (Print)
IS  - 0100-879X (Linking)
VI  - 48
IP  - 10
DP  - 2015 Oct
TI  - Salvaged single-unit cord blood transplantation for 26 patients with hematologic 
      malignancies not in remission.
PG  - 871-6
LID - S0100-879X2015001000002 [pii]
LID - 10.1590/1414-431X20154389 [doi]
AB  - Treatments for patients with hematologic malignancies not in remission are 
      limited, but a few clinical studies have investigated the effects of salvaged 
      unrelated cord blood transplantation (CBT). We retrospectively studied 19 
      patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with 
      refractory anemia with excess blasts [RAEB]), and 2 with non-Hodgkin's lymphoma 
      who received 1 CBT unit </= 2 loci human leukocyte antigen (HLA)-mismatched after 
      undergoing myeloablative conditioning regimens between July 2005 and July 2014. 
      All of them were in non-remission before transplantation. The infused total 
      nucleated cell (TNC) dose was 4.07 (range 2.76-6.02) x 10(7)/kg and that of CD34(+) 
      stem cells was 2.08 (range 0.99-8.65) x 10(5)/kg. All patients were engrafted with 
      neutrophils that exceeded 0.5 x 10(9)/L on median day +17 (range 14-37 days) and 
      had platelet counts of >20 x 10(9)/L on median day +35 (range 17-70 days). Sixteen 
      patients (61.5%) experienced pre-engraftment syndrome (PES), and six (23.1%) 
      patients progressed to acute graft-versus-host disease (GVHD). The cumulative 
      incidence rates of II-IV acute GVHD and chronic GVHD were 50% and 26.9%, 
      respectively. After a median follow-up of 27 months (range 5-74), 14 patients 
      survived and 3 relapsed. The estimated 2-year overall survival (OS), disease-free 
      survival (DFS), and non-relapse mortality (NRM) rates were 50.5%, 40.3%, and 
      35.2%, respectively. Salvaged CBT might be a promising modality for treating 
      hematologic malignancies, even in patients with a high leukemia burden.
FAU - Yao, W
AU  - Yao W
AD  - School of Medicine, Shandong University, Jinan, CN.
FAU - Zheng, C C
AU  - Zheng CC
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Liu, H L
AU  - Liu HL
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Geng, L Q
AU  - Geng LQ
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Tang, B L
AU  - Tang BL
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Tong, J
AU  - Tong J
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Zhu, X Y
AU  - Zhu XY
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Song, K D
AU  - Song KD
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Qiang, P
AU  - Qiang P
AD  - Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, 
      Hefei, CN.
FAU - Sun, Z M
AU  - Sun ZM
AD  - School of Medicine, Shandong University, Jinan, CN.
LA  - eng
PT  - Clinical Study
PT  - Journal Article
DEP - 20150327
PL  - Brazil
TA  - Braz J Med Biol Res
JT  - Brazilian journal of medical and biological research = Revista brasileira de 
      pesquisas medicas e biologicas
JID - 8112917
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Allografts
MH  - Anemia, Refractory, with Excess of Blasts/mortality/*therapy
MH  - Child
MH  - *Cord Blood Stem Cell Transplantation/mortality
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - *Graft vs Host Disease/mortality
MH  - Hematologic Neoplasms/mortality/therapy
MH  - Humans
MH  - Leukemia/mortality/therapy
MH  - Leukemia, Biphenotypic, Acute/mortality/*therapy
MH  - Leukemia, Lymphoid/mortality/therapy
MH  - Leukemia, Myeloid/mortality/therapy
MH  - Lymphoma, Non-Hodgkin/mortality/*therapy
MH  - Male
MH  - Myelodysplastic Syndromes/mortality/therapy
MH  - Remission Induction/methods
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4617112
EDAT- 2015/10/09 06:00
MHDA- 2016/03/26 06:00
PMCR- 2015/03/27
CRDT- 2015/10/08 06:00
PHST- 2014/09/29 00:00 [received]
PHST- 2015/01/13 00:00 [accepted]
PHST- 2015/10/08 06:00 [entrez]
PHST- 2015/10/09 06:00 [pubmed]
PHST- 2016/03/26 06:00 [medline]
PHST- 2015/03/27 00:00 [pmc-release]
AID - S0100-879X2015001000002 [pii]
AID - 10.1590/1414-431X20154389 [doi]
PST - ppublish
SO  - Braz J Med Biol Res. 2015 Oct;48(10):871-6. doi: 10.1590/1414-431X20154389. Epub 
      2015 Mar 27.